| No. of tumors with nucleotide substitutions | No. of cases examined | |||||||||
| A:T > C:G | A:T > G:C | A:T > T:A | G:C > A:T at CpG | G:C > A:T at non CpG | G:C > C:G | G:C > T:A | ins/del | Others | ||
| The present study | 8% | 20% | 4% | 20% | 16% | 4% | 24% | 4% | 0% | 25 |
| Olshan (CanEpiBioPre 1997) | 4% | 13% | 8% | 14% | 18% | 9% | 17% | 12% | 5% | 286 |
| IARC database (HNSCC) | 3% | 9% | 6% | 18% | 17% | 6% | 24% | 16% | 1% | 614 |
| IARC database (All primary sites) | 4% | 11% | 5% | 25% | 20% | 7% | 14% | 11% | 2% | 26,597 |